EUCTR2013-000717-20-BG进行中（未招募）1 期
A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LACOSAMIDE AS ADJUNCTIVE THERAPY IN SUBJECTS WITH EPILEPSY =1 MONTH TO <4 YEARS OF AGE WITH PARTIAL-ONSET SEIZURES
CB Biosciences Inc.0 个研究点目标入组 255 人开始时间: 2015年12月8日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 255
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subject is male or female from =1 month (ie, 4 weeks after full term [37 weeks gestational age]) to <4 years of age.
- •Subject has a diagnosis of epilepsy with partial-onset seizures. The results of =1 prior EEG and =1 magnetic resonance imaging/computerized tomography scan should be consistent with this diagnosis.
- •Subject weighs =4kg to <30kg at Visit 1.
- •Subject has experienced =2 partial-onset seizures with or without secondary generalization during each consecutive 7-day period during the 2 weeks prior to Visit 1.
- •Subject has =2 partial-onset seizures with or without secondary generalization during the End-of-Baseline video-EEG. Electrographic seizures are defined as recognizable ictal patterns on an EEG involving =2 contiguous electrodes. The seizures are initiated as a unilateral or strongly asymmetric abnormal epileptiform discharge lasting a total of >10 seconds.
- •Subject is on a stable (concurrently or sequentially) dosage regimen of 1 to 3 AEDs. The dosage regimen of concomitant AED therapy must be kept constant for a period of =2 weeks prior to Visit 1. A stable daily dosage regimen of a concomitant benzodiazepine (BZD) will be considered as a concomitant AED.
- •Vagus nerve stimulation is allowed and will not be counted as a concomitant AED. The VNS device must have been implanted for =6 months prior to Visit 1; device settings must be kept stable for =2 weeks prior to Visit 1 and kept stable during the Baseline, Treatment, and Transition Periods. Use of the VNS device magnet is allowed.
- •Subject is an acceptable candidate for venipuncture
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 244
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Subject has experienced febrile seizures exclusively. The occurrence of febrile seizures in addition to partial-onset seizures is not exclusionary.
- •Subject is on a ketogenic diet that has either changed within the 4 weeks prior to Visit 1 or is expected to change during the study.
- •Subject has creatinine clearance <30mL/minute.
- •Subject has a clinically relevant ECG abnormality, in the opinion of the investigator (eg, second or third degree heart block at rest or a corrected QT interval [QTc] =450ms).
- •Subject has a hemodynamically significant congenital heart disease.
- •Subject has an arrhythmic heart condition requiring medical therapy.
- •Subject has a known history of severe anaphylactic reaction secondary to medication intake or serious blood dyscrasias.
- •Subject has nonepileptic events that could be confused with seizures. Subjects may be included if epileptic events can be clearly distinguished and the frequency meets the study inclusion criteria.
- •Subject has a current diagnosis of Lennox-Gastaut syndrome, epilepsia partialis continua, primary generalized epilepsy, Dravet Syndrome or seizures that are not of partial-onset origin.
- •Subject has a history of status epilepticus =2 months prior to Screening (Visit 1).
- •Subject has been treated with ethosuximide.
- •Subject is currently being treated with vigabatrin or has discontinued use <12 months prior to Visit 1. Subjects who were previously treated with vigabatrin and have discontinued use >12 months prior to Visit 1 are eligible.
- •Subject has been treated with felbamate and has experienced any serious toxicity issues (defined as liver failure, aplastic anemia) with this treatment. Subjects treated with felbamate for <12 months are excluded. Subjects treated with felbamate for =12 months prior to Visit 1 and who have not experienced serious toxicity issues are eligible.
- •Subject has an acute or subacutely progressive central nervous system disease. Subject has epilepsy secondary to a progressing cerebral disease or any other progressively neurodegenerative disease (malignant brain tumor or Rasmussen Syndrome).
- •Subject has a known sodium channelopathy, such as Brugada syndrome.
研究者
相似试验
进行中（未招募）
不适用
A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, CROSSOVER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF 14-DAY INHALED TPI ASM8 IN SUBJECTS WITH ASTHMA - NDMedDRA version: 9.1Level: LLTClassification code 10003553Term: AsthmaasthmaEUCTR2007-005094-54-ITTOPIGEN PHARMACEUTICALS INC.18
进行中（未招募）
1 期
A Study of Idasanutlin with Cytarabine versus Cytarabine plus Placebo in Patients with Relapsed or Refractory Acute Myeloid Leukemia.Relapsed or refractory acute myeloid leukemia (AML).MedDRA version: 21.0 Level: LLT Classification code 10000886 Term: Acute myeloid leukemia System Organ Class: 100000004864EUCTR2014-003065-15-ATF. Hoffmann-La Roche Ltd440
进行中（未招募）
1 期
EFFICACY AND SAFETY OF LACOSAMIDE AS ADJUNCTIVE THERAPY IN SUBJECTS =1 MONTH TO <4 YEARS WITH PARTIAL-ONSET SEIZURESEpilepsy with partial onset seizuresMedDRA version: 18.0Level: PTClassification code 10015037Term: EpilepsySystem Organ Class: 10029205 - Nervous system disordersEUCTR2013-000717-20-FRCB Biosciences Inc.244
进行中（未招募）
1 期
A Study of Idasanutlin with Cytarabine versus Cytarabine plus Placebo in Patients with Relapsed or Refractory Acute Myeloid Leukemia.EUCTR2014-003065-15-ESRoche Farma, S.A., que representa en España a F. Hoffmann-La Roche Ltd.440
进行中（未招募）
1 期
A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF INTRAVENOUS CR845 IN HEMODIALYSIS PATIENTS WITH MODERATE-TO-SEVERE PRURITUS, WITH A 52-WEEK OPEN-LABEL EXTENSIOEUCTR2018-001930-17-HUCara Therapeutics INC350